Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Orange Book Patents
Across 5 drugs with upcoming expirations
Activity
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Regulatory
Oruvail — ACTRON
Application NDA020499 (NDA)
Oruvail — ORUDIS KT
Application NDA020429 (NDA)
Lodine — LODINE XL
Application NDA020584 (NDA)
Effexor — EFFEXOR XR
Application NDA020699 (NDA)
Protonix — PROTONIX
Application NDA020987 (NDA)
Protonix — PROTONIX IV
Application NDA020988 (NDA)
Inderal — INNOPRAN XL
Application NDA021438 (NDA)
Cordarone — AMIODARONE HYDROCHLORIDE
Application NDA021594 (NDA)
Protonix — PROTONIX
Application NDA022020 (NDA)
Cordarone — NEXTERONE
Application NDA022325 (NDA)
Effexor — VENLAFAXINE HYDROCHLORIDE
Application NDA022104 (NDA)
Oruvail — NEXCEDE
Application NDA022470 (NDA)
Suprax — SUPRAX
Application NDA203195 (NDA)
Suprax — SUPRAX
Application NDA202091 (NDA)
Inderal — HEMANGEOL
Application NDA205410 (NDA)
Mylotarg — MYLOTARG
Application BLA761060 (BLA)
Besponsa — BESPONSA
Application BLA761040 (BLA)
Protonix — PANTOPRAZOLE SODIUM
Application NDA209463 (NDA)
Effexor — VENLAFAXINE BESYLATE
Application NDA215429 (NDA)
Protonix — PANTOPRAZOLE SODIUM IN 0.9% SODIUM CHLORIDE
Application NDA217512 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)